Literature DB >> 33539876

Biophysical and Structural Characterization of Novel RAS-Binding Domains (RBDs) of PI3Kα and PI3Kγ.

Nicholas G Martinez1, David F Thieker2, Leiah M Carey2, Juhi A Rasquinha1, Samantha K Kistler1, Brian A Kuhlman2, Sharon L Campbell3.   

Abstract

Phosphatidylinositol-3-kinases (PI3Ks) are lipid kinases that phosphorylate phosphatidylinositol 4,5-bisphosphate to generate a key lipid second messenger, phosphatidylinositol 3,4,5-bisphosphate. PI3Kα and PI3Kγ require activation by RAS proteins to stimulate signaling pathways that control cellular growth, differentiation, motility and survival. Intriguingly, RAS binding to PI3K isoforms likely differ, as RAS mutations have been identified that discriminate between PI3Kα and PI3Kγ, consistent with low sequence homology (23%) between their RAS binding domains (RBDs). As disruption of the RAS/PI3Kα interaction reduces tumor growth in mice with RAS- and epidermal growth factor receptor driven skin and lung cancers, compounds that interfere with this key interaction may prove useful as anti-cancer agents. However, a structure of PI3Kα bound to RAS is lacking, limiting drug discovery efforts. Expression of full-length PI3K isoforms in insect cells has resulted in low yield and variable activity, limiting biophysical and structural studies of RAS/PI3K interactions. This led us to generate the first RBDs from PI3Kα and PI3Kγ that can be expressed at high yield in bacteria and bind to RAS with similar affinity to full-length PI3K. We also solved a 2.31 Å X-ray crystal structure of the PI3Kα-RBD, which aligns well to full-length PI3Kα. Structural differences between the PI3Kα and PI3Kγ RBDs are consistent with differences in thermal stability and may underly differential RAS recognition and RAS-mediated PI3K activation. These high expression, functional PI3K RBDs will aid in interrogating RAS interactions and could aid in identifying inhibitors of this key interaction.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  RAS; cancer; cell signaling; phosphoinositide 3-kinase (PI3K); protein/protein interactions

Mesh:

Substances:

Year:  2021        PMID: 33539876      PMCID: PMC8005443          DOI: 10.1016/j.jmb.2021.166838

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  49 in total

Review 1.  RAS/Effector Interactions from Structural and Biophysical Perspective.

Authors:  Ariel Erijman; Julia M Shifman
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

2.  The small GTPases K-Ras, N-Ras, and H-Ras have distinct biochemical properties determined by allosteric effects.

Authors:  Christian W Johnson; Derion Reid; Jillian A Parker; Shores Salter; Ryan Knihtila; Petr Kuzmic; Carla Mattos
Journal:  J Biol Chem       Date:  2017-06-19       Impact factor: 5.157

3.  Knowledge-based protein secondary structure assignment.

Authors:  D Frishman; P Argos
Journal:  Proteins       Date:  1995-12

4.  Protein sequence alignments: a strategy for the hierarchical analysis of residue conservation.

Authors:  C D Livingstone; G J Barton
Journal:  Comput Appl Biosci       Date:  1993-12

5.  Thermodynamics of Ras/effector and Cdc42/effector interactions probed by isothermal titration calorimetry.

Authors:  M G Rudolph; T Linnemann; P Grunewald; A Wittinghofer; I R Vetter; C Herrmann
Journal:  J Biol Chem       Date:  2001-04-05       Impact factor: 5.157

6.  Molecular mechanism of activation of class IA phosphoinositide 3-kinases (PI3Ks) by membrane-localized HRas.

Authors:  Braden D Siempelkamp; Manoj K Rathinaswamy; Meredith L Jenkins; John E Burke
Journal:  J Biol Chem       Date:  2017-05-17       Impact factor: 5.157

7.  Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110gamma.

Authors:  Barbara Kurig; Aliaksei Shymanets; Thomas Bohnacker; Carsten Brock; Mohammad Reza Ahmadian; Michael Schaefer; Antje Gohla; Christian Harteneck; Matthias P Wymann; Elisabeth Jeanclos; Bernd Nürnberg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-11       Impact factor: 11.205

8.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

9.  The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.

Authors:  Jill Hallin; Lars D Engstrom; Lauren Hargis; Andrew Calinisan; Ruth Aranda; David M Briere; Niranjan Sudhakar; Vickie Bowcut; Brian R Baer; Joshua A Ballard; Michael R Burkard; Jay B Fell; John P Fischer; Guy P Vigers; Yaohua Xue; Sole Gatto; Julio Fernandez-Banet; Adam Pavlicek; Karen Velastagui; Richard C Chao; Jeremy Barton; Mariaelena Pierobon; Elisa Baldelli; Emanuel F Patricoin; Douglas P Cassidy; Matthew A Marx; Igor I Rybkin; Melissa L Johnson; Sai-Hong Ignatius Ou; Piro Lito; Kyriakos P Papadopoulos; Pasi A Jänne; Peter Olson; James G Christensen
Journal:  Cancer Discov       Date:  2019-10-28       Impact factor: 38.272

10.  Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer.

Authors:  Miguel M Murillo; Sareena Rana; Bradley Spencer-Dene; Emma Nye; Gordon Stamp; Julian Downward
Journal:  Cell Rep       Date:  2018-12-26       Impact factor: 9.423

View more
  1 in total

1.  Cryo-EM structures of PI3Kα reveal conformational changes during inhibition and activation.

Authors:  Xiao Liu; Su Yang; Jonathan R Hart; Yingna Xu; Xinyu Zou; Huibing Zhang; Qingtong Zhou; Tian Xia; Yan Zhang; Dehua Yang; Ming-Wei Wang; Peter K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-09       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.